These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 39251080)

  • 1. The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.
    Low ZXB; Ng WS; Lim ESY; Goh BH; Kumari Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Sep; ():111139. PubMed ID: 39251080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions involving classic psychedelics: A systematic review.
    Halman A; Kong G; Sarris J; Perkins D
    J Psychopharmacol; 2024 Jan; 38(1):3-18. PubMed ID: 37982394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies.
    Weleff J; Akiki TJ; Barnett BS
    J Psychoactive Drugs; 2023; 55(4):434-444. PubMed ID: 36218281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.
    Hinkle JT; Graziosi M; Nayak SM; Yaden DB
    JAMA Psychiatry; 2024 Sep; ():. PubMed ID: 39230883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
    Wilkes R; Roberts DM; Liknaitzky P; Brett J
    Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
    Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ
    Biomed Pharmacother; 2023 Dec; 169():115775. PubMed ID: 37944438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.
    Zhornitsky S; Oliva HNP; Jayne LA; Allsop ASA; Kaye AP; Potenza MN; Angarita GA
    Front Psychiatry; 2023; 14():1197890. PubMed ID: 37435405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities.
    Szabo A
    Front Immunol; 2015; 6():358. PubMed ID: 26236313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.
    Caspani G; Ruffell SGD; Tsang W; Netzband N; Rohani-Shukla C; Swann JR; Jefferies WA
    Pharmacol Res; 2024 Sep; 207():107338. PubMed ID: 39111558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classic psychedelics do not affect T cell and monocyte immune responses.
    Rudin D; Areesanan A; Liechti ME; Gründemann C
    Front Psychiatry; 2023; 14():1042440. PubMed ID: 36741125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of classic psychedelics among adults: a Danish online survey study.
    Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
    Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.
    Vamvakopoulou IA; Nutt DJ
    Eur Addict Res; 2024; 30(5):302-320. PubMed ID: 39321788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.
    Holze F; Singh N; Liechti ME; D'Souza DC
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):472-489. PubMed ID: 38301886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.
    Hovmand OR; Poulsen ED; Arnfred S
    J Psychopharmacol; 2024 Jan; 38(1):19-32. PubMed ID: 37969069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scoping Review: The Role of Psychedelics in the Management of Chronic Pain.
    Robinson CL; Fonseca ACG; Diejomaoh EM; D'Souza RS; Schatman ME; Orhurhu V; Emerick T
    J Pain Res; 2024; 17():965-973. PubMed ID: 38496341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.